We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Department of Pharmacology, S.V.U.College of Pharmaceutical Sciences, S.V.University, Tirupati - 517502. A.P, India.
White patches emerge as a result of melanin loss in vitiligo, a chronic skin disorder. This happens when melanocytes—the cells that make pigment—are harmed or killed. Vitiligo is frequently linked to autoimmune mechanisms, in which the body's immune system attacks its own cells, even though the exact reason is yet unknown. Its onset is also believed to be significantly influenced by oxidative stress, environmental variables, and genetics. People of any age or background might be affected by the disorder, which can progress slowly or quickly. Based on the distribution of depigmented areas, it can be roughly classified into segmental and non-segmental forms. Although vitiligo is not contagious and does not directly endanger physical health.
Pain is defined as a subjective and unpleasant sensory as well as emotional experience that is linked to actual or potential tissue injury.[1] The transmission of pain signals occurs through four primary stages: transduction, transmission, modulation, and perception. In the transduction phase, nociceptors recognize harmful stimuli and convert them into electrical nerve impulses. These impulses are then conveyed to the spinal cord via Aδ and C fibres and subsequently travel through the spinothalamic tract to reach the thalamus.[2]During the transmission phase, these signals can be altered through various modulatory mechanisms that influence how pain is ultimately experienced. Modulation takes place at multiple levels within the nervous system and involves processes such as activation of opioid receptors by endogenous and exogenous opioids, autonomic nervous system responses, and regulation of N-methyl-D-aspartate (NMDA) receptors along with gamma-aminobutyric acid (GABA) signalling pathways.[3] Once the signals reach the brain, perception occurs. This stage involves several cortical and subcortical regions that not only interpret the pain signals but also dynamically regulate them.Analgesic medications act at different points along this pain pathway to decrease pain intensity. Although opioids remain a key component in managing moderate to severe pain, their use is associated with several limitations, including tolerance, dependence, respiratory depression, and opioid-induced hyperalgesia [4]. Furthermore, the ongoing opioid crisis has emphasized the need for safer and effective alternatives for pain management.Depending on the nature of the pain, non-opioid therapeutic options may include first-line analgesics as per the analgesic ladder, as well as non-selective sodium channel blockers such as lidocaine, mexiletine, and carbamazepine, along with gabapentin and antidepressants [5]. The World Health Organization (WHO) analgesic ladder provides a structured, stepwise strategy for pain management, as illustrated in Figure 1, including the positioning of suzetrigine.Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol exert their effects by inhibiting enzymes involved in inflammation, namely cyclooxygenase (COX) and peroxidase (POX). Local anesthetics prevent the propagation of pain signals by blocking sodium channels, whereas gabapentin acts by inhibiting calcium channels and modulating glutamate release. Additionally, NMDA receptor antagonists like ketamine, as well as opioids, play a role in modulating pain pathways and reducing pain perception.[3]Effective pain management requires a careful balance between achieving sufficient analgesia and minimizing adverse effects. Recent research has identified NaV1.8, a specific voltage-gated sodium channel, as a crucial contributor to pain signalling. Targeting this channel has opened new possibilities for pain relief. Drugs such as suzetrigine, which selectively inhibit NaV1.8, may provide significant therapeutic benefits.Suzetrigine is an orally administered, highly selective NaV1.8 inhibitor, demonstrating over 31,000-fold selectivity compared to other sodium channel subtypes.[6] It has recently emerged as a novel analgesic and has received FDA approval for the treatment of moderate-to-severe acute pain.[7] As a non-opioid analgesic, suzetrigine specifically blocks the Nav1.8 channel in peripheral sensory neurons with high precision. Several sodium channel subtypes are known to play important roles in both acute inflammatory pain and chronic pain conditions, particularly neuropathic pain. The key advantage of selective Nav channel blockers lies in their reduced off-target effects, especially those involving the cardiovascular system and central nervous system (CNS) [8]. Although suzetrigine is promoted as a non-opioid analgesic without addictive potential or significant CNS-related adverse effects, the available evidence supporting these claims remains somewhat unclear and warrants further critical evaluation.[9] Therefore, although suzetrigine represents the first analgesic to gain FDA approval in more than 25 years, its introduction should be approached with cautious optimism. In the context of the ongoing opioid crisis, where targeted interventions have produced variable outcomes, an important question arises: how should regulatory bodies such as the FDA strike a balance between the urgent demand for non-opioid analgesics and the necessity for robust, evidence-based validation? The FDA approval of suzetrigine (initially designated VX-548) was primarily supported by two phase 2, placebo-controlled, double-blind randomized clinical trials. These studies demonstrated statistical significance within treatment groups; however, the extent of clinical benefit remained uncertain, particularly in the management of postoperative pain following bunionectomy and abdominoplasty. This uncertainty stems from reliance on summed differences in pain intensity scores, for which standardized or clinically meaningful effect sizes have not been clearly established.[7,9]While these trials possess certain methodological strengths, notable limitations in both design and interpretation reduce the reliability and generalizability of their findings, thereby necessitating careful evaluation. The treatment arms investigated included placebo, an active comparator consisting of acetaminophen combined with hydrocodone (5–325 mg administered every 6 hours), and varying doses of suzetrigine. The dosing regimens for suzetrigine included a high-dose protocol (100 mg loading dose followed by 50 mg every 12 hours), a medium-dose protocol (60 mg loading dose followed by 30 mg every 12 hours), and a low-dose protocol (20 mg loading dose followed by 10 mg every 12 hours), the latter being evaluated only in the bunionectomy trial.[9]Across both studies, only the high-dose suzetrigine regimen demonstrated superiority over placebo during the 48-hour postoperative assessment period. Although the inclusion of an active comparator is a methodological strength, the comparison between treatment arms raises concerns due to fundamental differences in pharmacological profiles and dosing adequacy. Specifically, the acetaminophen–hydrocodone combination not only failed to show superiority over placebo but also represented a relatively low opioid dose for postoperative pain management. This limited efficacy of the comparator highlights the need for more appropriate and clinically relevant comparators that better reflect standard care practices. Further limitations arise from the selection of surgical models, namely bunionectomy and abdominoplasty, and the restriction of outcome assessment to the initial 48 hours following surgery. These factors significantly constrain the external validity of the findings, as they do not adequately represent more complex and commonly performed procedures, such as major joint arthroplasty or spinal surgeries, where postoperative pain often persists for extended periods and presents greater therapeutic challenges.[10] The short duration of these studies is particularly concerning, given that the FDA extrapolated these findings to support the broader use of suzetrigine in diverse acute pain conditions.Another important issue is the lack of transparency regarding the use of non-steroidal anti-inflammatory drugs (NSAIDs) as rescue analgesics during the trials. The potential use of such adjunctive therapies may confound the results, making it difficult to attribute the observed analgesic effects solely to suzetrigine. Moreover, the industry-sponsored nature of these trials introduces an inherent risk of bias. Sponsors’ direct involvement in data access and analysis (NCT04988336, NCT05034952) raises concerns regarding selective outcome reporting and possible conflicts of interest.[11]
SIGNIFICANCE:
Nav1.8 sodium channels are highly expressed in primary pain-sensing neurons. Suzetrigine is a potent and highly selective Nav1.8 inhibitor that has recently been approved by the Food and Drug Administration for treating acute pain. We find that suzetrigine reduces but does not completely block electrical excitability of human dorsal root ganglion neurons, in part because robust action potentials can be generated by other types of sodium channels in the neurons, including Nav1.7 channels. The results suggest that inhibition of Nav1.8 channels alone may produce only limited reduction of pain signalling by primary pain-sensing neurons.
FIGURE 1: The WHO analgesic ladder with the proposed positioning ofSuzetrigine
MECHANISM OF ACTION:
Pain should not be considered a single, isolated event, but rather the outcome of a complex, multistage process involving transduction, transmission, and perception. The physiological process responsible for detecting noxious stimuli is termed nociception, whereas pain refers to the subjective experience arising from the integration of sensory and emotional components. Noxious stimuli, including thermal, mechanical, or inflammatory insults, are detected by peripheral nociceptors and converted into electrical signals during the transduction phase. These signals are transmitted via small-diameter Aδ and C fibres to the dorsal horn of the spinal cord, where the release of excitatory neurotransmitters such as glutamate, substance P, and calcitonin gene-related peptide (CGRP) leads to activation of second-order neurons.[12]From the spinal cord, pain signals ascend through pathways such as the spinothalamic tract to reach the ventral posterior nuclei of the thalamus. Subsequently, these signals are relayed to the somatosensory cortex, where the localization and intensity of pain are processed. In addition to this, signals are distributed to other brain regions that modulate the overall pain experience. Connections to the limbic system contribute to the emotional aspects of pain, whereas projections to the prefrontal cortex influence attention and behavioural responses associated with pain perception.[13]At every stage of this pathway, neuronal excitability is tightly regulated by ion channel activity, particularly voltage-gated sodium channels, which are essential for the initiation and propagation of action potentials. Among the nine identified subtypes of voltage-gated sodium channels (Nav1.1–Nav1.9), Nav1.7, Nav1.8, and Nav1.9 are predominantly expressed in peripheral sensory neurons.[14] Evidence from human genetic studies underscores their significance: gain-of-function mutations in the SCN9A gene (encoding Nav1.7) are associated with erythromelalgia, a condition characterized by severe burning pain, whereas loss-of-function mutations result in congenital insensitivity to pain.[15]Nav1.8, encoded by the SCN10A gene, is responsible for generating persistent sodium currents in C-fibres and plays a crucial role in maintaining high-frequency neuronal firing, thereby contributing significantly to nociceptive signalling.[16] These channels are primarily localized in the dorsal root ganglion (DRG) and are directly involved in mediating acute pain, as illustrated in Figure 1. Experimental studies in animal models have demonstrated that the absence of Nav1.8 leads to a marked reduction in acute pain responses. Furthermore, because Nav1.8 channels are not expressed within the central nervous system, the likelihood of central adverse effects is theoretically reduced. Leveraging this understanding, Vertex Pharmaceuticals developed suzetrigine as a highly selective Nav1.8 antagonist for clinical use in humans.Suzetrigine demonstrates potent inhibition of human Nav1.8 sodium currents at sub-nanomolar concentrations, with an IC?? of approximately 0.68 nM in human dorsal root ganglion (DRG) neurons and around 0.75 nM in non-human primates, while exhibiting comparatively lower potency in rodent models. Notably, it displays an exceptional degree of selectivity, exceeding 31,000-fold preference for Nav1.8 over other Nav channel subtypes and more than 180 additional molecular targets. This high level of selectivity significantly reduces the likelihood of off-target effects, particularly those involving cardiac sodium channels such as Nav1.5.Structural investigations employing chimeric Nav1.8/Nav1.2 channel constructs have identified the drug-binding region within the voltage-sensing domain 2 (VSD2), specifically localized to the S3–S4 linker region, thereby revealing a distinct and previously uncharacterized binding motif [17].
FIGURE 2: Mechanism of action of suzetrigine.; Suzetrigine selectively inhibits the Nav1.8 peripheral sodium channel.
Binding studies further confirmed a direct interaction, with a dissociation constant (Kd) of approximately 65 nM for the isolated VSD2 domain. Electrophysiological analyses indicate that suzetrigine preferentially associates with Nav1.8 channels in their closed (resting) state, stabilizing this conformation and resulting in tonic inhibition of channel activity.Repeatedstimulation at 5 Hz produced consistent levels of inhibition across successive pulses, without evidence of cumulative use-dependent block, supporting an allosteric mechanism of action rather than direct pore occlusion. Comparative compounds such as LTGO-33 and A-887826 exhibit distinct patterns of state dependence, whereas suzetrigine uniquely promotes stabilization of the closed-state conformation. VX-548 similarly demonstrates pronounced state-dependent inhibition, particularly favouring closed and inactivated channel states.[18,19]Further investigations revealed that suzetrigine exhibits reverse use-dependence, wherein repetitive depolarization can partially relieve channel inhibition. However, this reversal requires substantial depolarizing stimuli and occurs with a time constant of approximately 40 ms. Re-establishment of inhibition at hyperpolarized membrane potentials occurs at a rate proportional to drug concentration, reflecting rapid drug rebinding. Mechanistically, relief of inhibition corresponds to drug dissociation from the channel, whereas inhibition reflects reassociation. These findings indicate strong state dependence, characterized by weak binding to fully activated channels and markedly higher affinity for channels in the resting state, distinguishing suzetrigine from conventional sodium channel inhibitors.Collectively these mechanistic studies confirm that suzetrigine effectively attenuates nociceptor excitability through highly selective blockade of Nav1.8 channels. Pharmacokinetically, suzetrigine is orally bioavailable and administered twice daily, achieving peak plasma concentrations within approximately 3 hours and reaching steady-state levels within about 3 days. [20] It exhibits extensive plasma protein binding (~99%) and a large volume of distribution. The drug is primarily metabolized by the cytochrome P450 enzyme CYP3A4 and is contraindicated in combination with strong CYP3A inhibitors due to the risk of increased systemic exposure.[16] Additionally, suzetrigine acts as a CYP3A inducer, raising the potential for clinically significant drug–drug interactions.Further research is required to clarify the role and clinical relevance of its active metabolites.Clinical evidence from Phase 3 randomized controlled trials, as reported by Bertoch et al., including bunionectomy and abdominoplasty models, demonstrated that suzetrigine provides analgesic efficacy comparable to opioid-based therapy (hydrocodone/acetaminophen), while significantly reducing pain scores and increasing the proportion of patients achieving at least 30% pain relief compared with placebo [21]. Moreover, a third single-arm Phase 3 study reported consistent and substantial analgesic effects across both surgical and non-surgical acute pain conditions, supporting its broader clinical applicability.[18]The safety profile of suzetrigine appears favourable, with adverse events generally mild and limited to peripheral manifestations such as pruritus, muscle spasms, elevated creatine kinase levels, rash, nausea, and headache. Importantly, data from over 2,400 participants revealed no evidence of central nervous system impairment, respiratory depression, or addictive potential. Even in preclinical models involving prolonged administration (up to 30 days) followed by abrupt discontinuation, no withdrawal-related behaviours were observed.Overall suzetrigine represents a mechanism-based analgesic approach, functioning as a potent allosteric inhibitor of peripheral Nav1.8 channels. By selectively suppressing nociceptor excitability with sub-nanomolar potency and exceptional specificity, it offers a promising alternative to conventional pain therapies.[17]
PHARMACOLOGY:
The chemical designation of suzetrigine is 4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl) [oxolane-2-carbonyl] [amino]pyridine-2-carboxamide. It possesses a molecular formula of C??H??F?N?O? and a molecular weight of 473.4 g/mol. Structurally, the molecule is characterized by a tetrahydrofuran (THF) ring system that is substituted at five distinct positions, which contributes to its distinctive chemical properties and pharmacological activity.[23]Suzetrigine is available as an immediate-release, film-coated oral formulation marketed under the brand name Journavx. Each tablet contains 50 mg of the active pharmaceutical ingredient, and currently, no alternative dosage forms have received approval from the Food and Drug Administration.[24] The dosing regimen for the management of acute pain was established based on findings from two Phase 2 clinical trials conducted in bunionectomy and abdominoplasty settings. These studies evaluated multiple dosing strategies consisting of an initial loading dose followed by maintenance dosing every 12 hours over a 36-hour period. Among the regimens tested, only the highest dose (100 mg loading dose followed by 50 mg every 12 hours) demonstrated a statistically significant reduction in pain compared to placebo.[25] Consequently, this dosing protocol was advanced into Phase 3 clinical evaluation.Preclinical investigations revealed that suzetrigine exhibits marked species-dependent differences in potency against Nav1.8 channels. In vitro studies using dorsal root ganglion (DRG) neurons demonstrated an IC?? of 0.68 nM in humans and 0.75 nM in non-human primates, whereas rodent Nav1.8 channels showed substantially lower sensitivity, with an IC?? of approximately 56 nM, representing nearly an 80-fold reduction in potency.[7]Due to this discrepancy, conventional rodent pain models were found to be less predictive of clinical efficacy, leading to greater reliance on human and non-human primate data for translational evaluation.The principal human metabolite, M6-SUZ, also demonstrates significant pharmacological activity at Nav1.8 channels, with an IC?? of approximately 2.5 nM in human DRG neurons. [26]This finding suggests that both the parent compound and its metabolite contribute meaningfully to the overall therapeutic effect. The observed species selectivity underscores the importance of incorporating human-relevant data in the development of peripherally acting sodium channel inhibitors.According to the FDA-approved prescribing information, following oral administration under fasting conditions, the median time to reach peak plasma concentration (Tmax) is approximately 3.0 hours, which is delayed to around 5.0 hours when administered with food. Steady-state plasma concentrations are typically achieved within 3 days of repeated dosing. [27]Preclinical pharmacokinetic studies have reported oral bioavailability of 69.5% in monkeys and 68.1% in dogs; however, absolute bioavailability in humans has not been publicly disclosed.Suzetrigine exhibits extensive plasma protein binding exceeding 99%, primarily to albumin and alpha-1-acid glycoprotein. This high degree of protein binding likely limits the fraction of free drug in circulation and contributes to its relatively prolonged elimination half-life of approximately 23.6 hours [26]. The drug also demonstrates a large apparent volume of distribution (approximately 495 L), indicating substantial penetration into tissues. Additionally, the mean plasma clearance has been reported to be 13.9 L/h. As outlined in the FDA integrated review, further characterization of its pharmacokinetic and metabolic profile remains an important area for ongoing investigation.
FIGURE 3: Pharmacology of suzetrigine. Pharmacologic properties at a glance
Preclinical investigations in animal models have demonstrated that suzetrigine is capable of penetrating the central nervous system in both non-human primates and canine species. [26] Despite this distribution, studies conducted in rats and monkeys revealed no evidence of central nervous system toxicity, abuse liability, or physical dependence, even at systemic exposures exceeding 50-fold higher than the therapeutic levels used in humans. In repeat-dose toxicity and withdrawal assessments, suzetrigine did not produce neurobehavioral alterations, withdrawal manifestations, or significant changes in physiological parameters such as body weight, temperature, or motor activity, findings that contrast with those observed in morphine-treated control groups.[17]These observations underscore the high degree of specificity of suzetrigine for peripherally expressed Nav1.8 channels.Consistent with preclinical findings, Phase 3 clinical trials reported a low incidence of adverse events related to abuse potential, with rates comparable to those observed in placebo-treated groups. Across these studies, there was no meaningful evidence of misuse, dependence, or withdrawal associated with suzetrigine administration. Cardiovascular safety was further supported by telemetry-based monitoring in non-human primates, which demonstrated no significant effects on blood pressure, electrocardiographic parameters, or respiratory function following both single and repeated dosing regimens. [17]A Phase 1 clinical study was conducted to evaluate the effect of suzetrigine on cardiac repolarization, specifically the QTc interval.[28] According to the prescribing information issued by the Food and Drug Administration, no clinically significant prolongation of the QTc interval was observed at doses up to twice the maximum recommended therapeutic level.[24]Suzetrigine undergoes extensive hepatic metabolism, primarily mediated by the cytochrome P450 enzyme CYP3A4. This metabolic pathway results in oxidative biotransformation and the formation of its principal active metabolite, pyridine N-oxide (M6-SUZ). This metabolite exhibits approximately 3.7-fold lower potency compared to the parent compound and is further metabolized via the same CYP3A4 pathway.[26] Given this metabolic profile, careful consideration is required when co-administering suzetrigine with other medications that act as substrates, inducers, or inhibitors of CYP3A4.Common analgesics that are substrates of CYP3A4, such as acetaminophen and codeine, may present challenges in multimodal pain management strategies when used alongside suzetrigine. Concomitant use with strong CYP3A4 inhibitors, including ketoconazole, is contraindicated due to the potential for significantly increased plasma concentrations of suzetrigine, which may elevate the risk of toxicity. Furthermore, suzetrigine itself functions as a moderate inducer of CYP3A4, potentially reducing the plasma levels and therapeutic efficacy of co-administered drugs that are metabolized through this pathway.[24]
PHARMACOKINETICS AND PHARMACODYNAMICS:
As of May 2025, the pharmacokinetic and pharmacodynamic characteristics of suzetrigine have been investigated across seven completed Phase I clinical trials (NCT06972212, NCT06820307, NCT05851157, NCT05704556, NCT05635110, NCT05560464, NCT05541471) [29,30], with additional studies currently ongoing. Following oral administration, suzetrigine is rapidly absorbed, achieving peak plasma concentrations (Tmax) at approximately 3 hours under fasting conditions. The maximum plasma concentration (Cmax) has been reported at 0.62 μg/mL, while the area under the plasma concentration–time curve (AUC) is approximately 11.5 μg·h/ml.The drug demonstrates a high apparent volume of distribution, indicative of extensive tissue distribution. Its pharmacokinetic profile is influenced by cytochrome P450 3A (CYP3A) activity, with reduced systemic exposure observed in the presence of CYP3A inducers, thereby necessitating dose adjustments or contraindications as outlined in Table 1. Hepatic impairment also significantly alters drug exposure; in patients with moderate hepatic dysfunction (Child–Pugh Class B), AUC increases by approximately 1.5-fold and Cmax by 1.3-fold. These findings emphasize the need for dose modification in this population, whereas the use of suzetrigine in patients with severe hepatic impairment (Child–Pugh Class C) remains contraindicated.[31,32]No clinically significant variations in pharmacokinetics have been identified based on demographic factors such as age, sex, body weight, or race, nor in individuals with mild renal or hepatic impairment. Pharmacokinetic data further indicate minimal penetration into the central nervous system, along with negligible effects on cardiac and skeletal muscle tissues, supporting a lower likelihood of adverse outcomes such as sedation or respiratory depression.The most frequently reported adverse effects include pruritus, muscle spasms, elevated creatine phosphokinase levels, and cutaneous rash. Patients receiving suzetrigine are advised to avoid the consumption of grapefruit or grapefruit-containing products due to potential interactions affecting CYP3A-mediated metabolism [33].
DOSAGE:
Phase II and Phase III clinical trials have systematically evaluated the efficacy and safety of multiple dosing regimens of suzetrigine for the management of acute postoperative pain.[5,6,34] Both phases consistently employed a standardized dosing protocol consisting of a 100 mg loading dose followed by 50 mg administered every 12 hours for a duration of 48 hours after surgery.In two Phase II trials conducted in patients undergoing abdominoplasty and hallux valgus correction procedures, a statistically significant reduction in pain intensity, measured using the summed pain intensity difference (SPID) over a 48-hour period, was observed exclusively in the high-dose treatment group when compared with placebo. [5] In contrast, lower dosing regimens failed to demonstrate meaningful superiority over either placebo or the active comparator consisting of hydrocodone in combination with acetaminophen.These findings were subsequently validated in two large-scale Phase III trials involving more than 2,000 participants. The high-dose regimen produced both rapid onset and sustained analgesic effects, showing clear superiority over placebo, although its efficacy was comparable to, or in some cases slightly less than, that achieved with hydrocodone combined with acetaminophen.[34] Based on the available clinical evidence, the dosing strategy of a 100 mg loading dose followed by 50 mg administered every 12 hours is currently regarded as the most effective regimen among those evaluated to date.[6]
EFFICACY:
Nav1.8 sodium channels constitute a highly promising therapeutic target for pain management owing to their predominant expression in primary sensory neurons and minimal distribution across other neuronal populations. Suzetrigine has demonstrated substantial efficacy in reducing pain in clinical studies and has shown greater potency compared to other agents with a similar mechanism of action, such as VX-150. A distinguishing pharmacodynamic feature of suzetrigine is its “reverse use-dependence,” whereby its inhibitory effect diminishes with repetitive depolarization. This phenomenon occurs with a time constant of approximately 40 milliseconds (ms) and is independent of drug concentration, whereas re-establishment of inhibition at hyperpolarized membrane potentials is concentration-dependent.
These findings indicate that suzetrigine exhibits strong binding affinity for Nav1.8 channels in the resting state, with significantly weaker interaction when voltage sensors are fully activated, reflecting a unique pattern of state-dependent channel inhibition.[35]The efficacy of suzetrigine has been further evaluated in two pivotal randomized controlled trials, NAVIGATE-1 and NAVIGATE-2, which included adult patients experiencing moderate-to-severe acute pain following abdominoplasty and bunionectomy procedures. In these studies, patients receiving suzetrigine at a regimen of a 100 mg loading dose followed by 50 mg every 12 hours reported significantly greater reductions in pain compared to placebo, as measured by the summed pain intensity difference over 48 hours (SPID48). In the abdominoplasty trial, the least squares mean difference (LSMD) between suzetrigine and placebo was 48.4 (p < 0.0001), whereas in the bunionectomy trial, the LSMD was 29.3 (p = 0.0002).In addition to greater overall pain reduction, suzetrigine demonstrated a more rapid onset of analgesic effect compared to placebo, with clinically meaningful decreases in Numeric Pain Rating Scale (NPRS) scores occurring within 2 to 4 hours, compared to approximately 8 hours with placebo. When compared with low-dose opioid therapy, specifically hydrocodone/acetaminophen (HB5/APAP325), suzetrigine exhibited comparable or slightly reduced efficacy depending on the surgical model; it showed superior performance in abdominoplasty but was less effective in bunionectomy procedures. A network meta-analysis further indicated that the analgesic efficacy of suzetrigine is comparable to that of non-steroidal anti-inflammatory drugs (NSAIDs), although somewhat lower than that achieved with higher-dose opioid regimens. Overall, suzetrigine was well tolerated, with a lower incidence of gastrointestinal adverse effects compared to opioids and a discontinuation rate of less than 1%. [36] a separate single-arm clinical study evaluating suzetrigine for the treatment of acute pain of both surgical and non-surgical origin, 83.2% of patients with moderate-to-severe pain rated the treatment as good, very good, or excellent according to the Patient Global Assessment (PGA) scale. Within this study, participants were permitted to use rescue medications, including acetaminophen (650 mg) and ibuprofen (400 mg), every six hours as needed for additional pain control. Notably, high levels of patient-reported satisfaction were observed irrespective of pain etiology, with 82.0% of surgical patients and 91.2% of non-surgical patients reporting favorable outcomes. Importantly, the efficacy of suzetrigine was not significantly influenced by the concurrent use of rescue medications. Only 1.6% of participants discontinued treatment due to insufficient efficacy, further supporting the favourable tolerability and effectiveness profile of suzetrigine.[37]
ADVERSE EFFECTS:
Preclinical evaluations conducted in rodent and non-human primate models demonstrated that suzetrigine is not associated with significant adverse effects or evidence of dependence liability.[38] No neurobehavioral, sedative, or stimulatory effects were identified in these studies. Furthermore, even at doses substantially exceeding therapeutic levels, abrupt discontinuation of suzetrigine did not result in manifestations of physical dependence. Long-term administration also revealed no detrimental effects on cardiovascular or respiratory parameters, including blood pressure and electrocardiographic (ECG) measurements. In Phase II clinical trials involving patients experiencing acute postoperative pain following abdominoplasty (n = 303) and hallux valgus correction surgery (n = 274), suzetrigine exhibited good tolerability and a favourable safety profile.[5]The most commonly reported adverse events (occurring in ≥10% of participants) included nausea, headache, constipation, dizziness, and vomiting.
These events were generally mild in severity, resolved either spontaneously or with supportive care, and did not necessitate treatment discontinuation. Isolated serious adverse events were reported, including pulmonary embolism in a patient receiving an average dose of suzetrigine, laryngeal stenosis in thehydrocodone/acetaminophen group, and cellulitis with sepsis in the placebo group; however,none of these events were considered related to the study medication. Notably, discontinuation rates were lower in the suzetriginetreated groups compared to both placebo and hydrocodone/acetaminophen groups.Additional clinical safety data further support the favourable tolerability of suzetrigine. In a separate study, most adverse events were classified as mild to moderate in intensity, with the most frequently reported being headache, constipation, nausea, falls, and rash. Among these, only headache occurred in more than 5% of participants (7.0%).[39]Serious adverse events were rare, occurring in only two patients (0.8%): one case of suicidal ideation and one instance of cellulitis. Both were determined to be unrelated to suzetrigine therapy.[37] Overall, adverse reactions appear to be dose-dependent and are typically mild to moderate in severity. Despite encouraging safety findings, certain concerns have been raised. In vitro data have suggested the potential for neurotoxicity at elevated concentrations, as well as a possible proarrhythmic risk. Additionally, similar to other sodium channel inhibitors, suzetrigine may carry a risk of hypersensitivity reactions, although this risk appears to be lower compared to agents such as lamotrigine. Given its primary hepatic metabolism, caution is advised when administering suzetrigine to patients with significant liver impairment, and its use may need to be avoided in severe cases.[38]Currently, there is a lack of clinical data regarding the safety of suzetrigine during pregnancy. As a result, potential teratogenic effects cannot be excluded, and the drug is contraindicated in pregnant women until further safety evidence becomes available.
INDICATIONS:
Effective management of acute pain necessitates a careful balance between achieving adequate analgesia and minimizing the risk of adverse effects.[40]Inadequately controlled pain may result in complications such as delayed recovery, extended hospitalization, and diminished quality of life.[41] Additionally, insufficient treatment of acute pain increases the likelihood of its progression to chronic pain, which is associated with substantial socio-economic burden. [42,43]Current approaches to acute pain management rely on a multimodal strategy that incorporates multiple classes of pharmacological agents, including non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, local anesthetics, and N-methyl-D-aspartate (NMDA) receptor antagonists.[3] Despite the availability of these therapeutic options, opioids continue to play a central role in the management of moderate-to-severe pain. However, their use is accompanied by a range of adverse effects, including sedation, respiratory depression, nausea, vomiting, constipation, and renal impairment.[44]Furthermore, opioid-based pain management in the United States is associated with a significant public health burden, contributing to approximately 85,000 new cases of opioid use disorder (OUD) annually. Managing pain in individuals with a history of substance use disorder remains particularly challenging due to the heightened risk of relapse and the limited availability of effective non-opioid alternatives.[45,46]Within this context, suzetrigine has emerged as a promising therapeutic candidate. Preclinical and early clinical evidence suggests that it produces analgesic effects through selective inhibition of peripheral voltage-gated sodium channels, without interaction with opioid receptors.[47]This mechanism is expected to reduce the risk of abuse and physical dependence compared with opioid analgesics, thereby positioning suzetrigine as a potentially valuable option for patients with a history of substance misuse.[48]Selective targeting of the Nav1.8 sodium channel has gained increasing attention as an innovative approach in pain management, with Nav1.8 inhibitors demonstrating the potential to provide effective and well-tolerated analgesia in both acute and chronic pain conditions.[49,50] Suzetrigine, in particular, shows promise in alleviating acute postoperative pain as well as chronic neuropathic pain, including conditions associated with neuralgia, diabetes, and peripheral nerve injury. Owing to its mechanism of action and favourable safety profile, it may be especially beneficial for patients experiencing moderate-to-severe pain in whom conventional therapies are ineffective, poorly tolerated, or contraindicated due to the risk of opioid dependence.[51,52]By selectively blocking Nav1.8 channels, suzetrigine enables targeted suppression of nociceptive signalling without inducing generalized central nervous system depression, distinguishing it from opioid-based therapies and establishing it as a novel alternative in pain management. Nevertheless, further large-scale clinical trials are required to comprehensively establish its efficacy and long-term safety. Additional data regarding its role in multimodal analgesic regimens, as well as its use in special populations such as pregnant and breastfeeding individuals, remain essential areas for future investigation.[6]
DRUG -DRUG INTERACTIONS:
Suzetrigine functions both as a substrate and an inducer of the cytochrome P450 3A4 (CYP3A4) enzyme, creating the potential for clinically significant drug–drug interactions. Concomitant administration with strong CYP3A4 inhibitors, such as ketoconazole, is contraindicated due to the risk of increased systemic exposure. In cases where moderate CYP3A4 inhibitors are co-administered, dose adjustments of suzetrigine are recommended. Additionally, the consumption of grapefruit or grapefruit-containing products should be avoided, as they inhibit CYP3A4 activity and may further elevate plasma drug concentrations. As a CYP3A4 inducer, suzetrigine has the potential to decrease the therapeutic effectiveness of drugs that are sensitive substrates of this enzyme, including midazolam. Particular caution is required when managing hormonal contraceptives, as suzetrigine may reduce their efficacy. Alternative or additional non-hormonal contraceptive methods are advised during treatment and for at least 28 days following discontinuation, especially for formulations other than those containing levonorgestrel or norethindrone.[53,54]The extent to which suzetrigine affects CYP3A4 substrates commonly used in the management of opioid use disorder, such as buprenorphine and methadone, has not yet been fully characterized. Ongoing pharmacokinetic investigations aim to further elucidate potential interactions between suzetrigine and other therapeutic agents, including the effects of concurrent administration of CYP450 enzyme inhibitors or inducers on its metabolism and bioavailability.[6]
ADVANTAGES OF SUZETRIGINE OVER EXISTING PAIN MEDICATION:
Suzetrigine represents a promising alternative to conventional opioid therapy for the management of moderate-to-severe acute pain, offering rapid and clinically meaningful analgesia while avoiding adverse effects such as sedation, euphoria, and the risk of dependence commonly associated with opioids.[45,37] Clinical investigations in postoperative settings, including abdominoplasty and bunionectomy, have demonstrated significant reductions in pain intensity, with summed pain intensity difference over 48 hours (SPID48) values reaching up to 48.4% (p < 0.001). Notably, the median onset of analgesic effect occurs within approximately two hours, achieving efficacy comparable to hydrocodone/acetaminophen while exhibiting improved tolerability and a lower incidence of adverse events.[45,55] In contrast to non-steroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics, suzetrigine exerts its effects through a targeted peripheral mechanism, selectively inhibiting Nav1.8 sodium channels located in dorsal root ganglion neurons. This selective blockade prevents the transmission of nociceptive signals without producing central nervous system-related side effects, thereby making it particularly advantageous for patients at increased risk of opioid dependence or adverse drug reactions.[31,35] Moreover, its favourable safety profile, lack of abuse potential, and potential utility in opioid-sparing therapeutic strategies position suzetrigine as a significant advancement in the field of acute pain management. In the context of the ongoing opioid crisis, it addresses the critical need for effective and non-addictive analgesic options. [37,55,56]
FUTURE PROSPECTS:
Following its approval by the Food and Drug Administration in January 2025 for the management of moderate-to-severe acute pain, suzetrigine is currently undergoing extensive clinical investigation to broaden its therapeutic scope. Two Phase III clinical trials are in progress to evaluate its efficacy in the treatment of painful diabetic peripheral neuropathy (DPN). One of these is a randomized, double-blind study (NCT06628908) comparing suzetrigine with pregabalin and placebo in adults aged 18–80 years diagnosed with DPN over a 12-week period, with primary endpoints focused on efficacy, safety, and tolerability.[57] The second is an open-label extension trial (NCT06696443), designed to assess the long-term safety and sustained effectiveness of suzetrigine in participants who have completed prior DPN studies.[58]Recent clinical findings have also indicated dose-dependent reductions in creatinine clearance among patients receiving suzetrigine for painful DPN, underscoring the importance of careful monitoring of renal function, particularly in individuals with pre-existing renal impairment.[59]In addition to neuropathic pain, suzetrigine is being investigated within multimodal analgesic strategies for postoperative pain management. A Phase IV open-label, single-arm study (NCT06887959) is currently evaluating its safety and effectiveness in controlling acute pain following laparoscopic and arthroscopic surgical procedures.[60] Furthermore, its role in aesthetic and reconstructive surgical settings is being explored in another Phase IV trial (NCT06887972), where it is incorporated into multimodal pain management protocols aimed at enhancing patient satisfaction and clinical outcomes.[61]Although suzetrigine represents a significant advancement in pain therapeutics, the broader understanding of pain pathophysiology—particularly in chronic and neuropathic conditions—remains incomplete. The substantial placebo responses observed in certain neuropathic pain trials highlight the need for more refined and translational human models that better capture disease heterogeneity. Consequently, while selective inhibition of Nav1.8 channels offers a promising non-opioid approach, there remains a critical need to identify and develop additional therapeutic targets to effectively address the diverse mechanisms underlying pain and to improve outcomes in patients who remain unresponsive to existing treatment modalities.
CONCLUSION
Suzetrigine represents a significant advancement in modern pain management as a novel, non-opioid analgesic targeting the peripheral NaV1.8 sodium channel. By selectively inhibiting this channel in dorsal root ganglion neurons, it effectively reduces nociceptor excitability while minimizing central nervous system adverse effects. Clinical trials have demonstrated that suzetrigine provides meaningful analgesia in acute postoperative pain, with efficacy comparable to conventional opioid combinations but with a superior safety profile. Importantly, it avoids key opioid-related risks such as respiratory depression, tolerance, and dependence, addressing critical concerns highlighted by the Opioid Crisis. However, limitations in trial design, short study duration, and variability in comparator efficacy necessitate cautious interpretation of current evidence. Additionally, its selective mechanism may not fully suppress pain due to the involvement of other sodium channel subtypes such as NaV1.7 channel. Despite these constraints, suzetrigine offers a promising opioid-sparing alternative, particularly in patients at high risk of adverse effects. Ongoing and future studies will be essential to establish its long-term safety, broader clinical utility, and role in chronic pain conditions. Overall, suzetrigine marks a paradigm shift toward mechanism-driven, targeted analgesic therapy.
REFERENCES
Dr Girish C, Sivamurthi T., Manoj kumar K., Charan K., Dr Sindhu. G., Current Perspectives on Pharmacological Innovation and Clinical Translation of Suzetrigine: A Selective Nav1.8 Inhibitor, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 4, 4256-4273, https://doi.org/10.5281/zenodo.19769053
10.5281/zenodo.19769053